undamentalytics Newsletter
Sign in

Verastem, Inc. revenue

Verastem, Inc.'s revenue was $30.9m in fiscal 2025, up 209.1% on the year before. Since fiscal 2018 ($26.7m) it has grown at a compound 2.5% a year. Over the last twelve months it was $87.5m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222024Dec 20242025Dec 2025LTMJun 2026
Revenue27178923103188
Growth on the year before—−34.7%+407.1%−97.7%+26.4%+285.2%+209.1%—
Gross profit27———————
Gross margin99.4%———————

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Verastem, Inc. $87.5m 26.4% 58.4%
Bicycle Therapeutics PLC $83.5m 194.7% 49.8%
4d Molecular Therapeutics, Inc. $92.0m 278712.1% 242.8%
Protalix Biotherapeutics, Inc. $80.6m 30.1% 6.1%
Ascentage Pharma Group International $79.9m -41.4% —
ADC Therapeutics SA $79.6m 3.0% —

Compare with peers

Head to head: BCYC vs VSTMFDMT vs VSTMPLX vs VSTM

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Verastem, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Verastem, Inc.